KRON News and Press, Kronos Bio Inc. From 02/01/22

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice pre...

Gainers: uCloudlink Group  (NASDAQ:UCL) +15%. Quantum-Si Incorporated QSI +10%. Micron Technology  MU +7%. Braze BRZE +6%. JAKKS Pacific (NASDAQ:JAKK) +6%. Losers: CytomX Therapeutics CTMX -29%. DBV Technologies  (NASDAQ:DBVT) -13%. Sigilon Therape...

Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies - Adds Mike Powell, Ph.D., as Executive Partner & promotes Francesco Draetta to Partner PR Newswire BOSTON , Dec. 17, 2021 /PRNewswire/ -- Omega F...

Data in the second half of 2023 could potentially lead to accelerated approval If approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit for intensive induction SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 06, 2021 ...

Initial data demonstrate long plasma half-life and dose-dependent target inhibition Trial is continuing to enroll patients on three-day on, four-day off schedule SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a co...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roshawn Blunt to the company’s Board of Directors. Ms. Blunt ...

Kronos Bio (NASDAQ:KRON): Q3 GAAP EPS of -$0.61 beats by $0.40. Press Release As of September 30, 2021, cash, cash equivalents and investments totaled $398.4M. For further details see: Kronos Bio EPS beats by $0.40

Company today announces progression of two discovery programs within its pipeline Highlights from the quarter include presentation of preclinical data on the company’s CDK9 inhibitor KB-0742 at AACR-NCI-EORTC meeting in October; Kronos Bio remains on track to report inter...

Kronos to receive broad access to Tempus’ real-world data and proprietary tools and materials to expand preclinical hypotheses testing capabilities and inform more streamlined clinical trial design Agreement builds on earlier collaboration between companies announced in Feb...

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Charles Lin, Ph.D., Senior Vice President, Biology, will participate in the Emerging Tr...